United States - English - NLM (National Library of Medicine)

jaifar international llc - alcohol 70% v/v, antiseptic - as a hand sanitizer gel for cleaning assistance. this product does not replace hand washing with soap and water.

Philippines - English - FDA (Food And Drug Administration)

ambica international corporation; distributor: daifarm inc. - clobetasol propionate - cream - 0.5 mg/g (0.05% w/w)

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - clindamycin phosphate - solution for injection - 150mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - clindamycin phosphate - solution for injection - 150mg/1ml

United States - English - NLM (National Library of Medicine)

greenstone llc - rifabutin (unii: 1w306tda6s) (rifabutin - unii:1w306tda6s) - rifabutin 150 mg - rifabutin capsules are indicated for the prevention of disseminated mycobacterium avium complex (mac) disease in patients with advanced hiv infection. rifabutin capsules are contraindicated in patients who have had clinically significant hypersensitivity to rifabutin or to any other rifamycins.

United States - English - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr), isoniazid (unii: v83o1voz8l) (isoniazid - unii:v83o1voz8l), pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - rifampin 120 mg - rifater is indicated in the initial phase of the short-course treatment of pulmonary tuberculosis. during this phase, which should last 2 months, rifater should be administered on a daily, continuous basis (see dosage and administration). following the initial phase and treatment with rifater, treatment should be continued with rifampin and isoniazid (e.g., rifamate) for at least 4 months. treatment should be continued for a longer period of time if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is hiv positive. in the treatment of tuberculosis, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. bacteriologic smears or cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to r

United States - English - NLM (National Library of Medicine)

american health packaging - rifabutin (unii: 1w306tda6s) (rifabutin - unii:1w306tda6s) - rifabutin 150 mg - rifabutin capsules usp are indicated for the prevention of disseminated mycobacterium avium complex (mac) disease in patients with advanced hiv infection. rifabutin capsules are contraindicated in patients who have had clinically significant hypersensitivity to rifabutin or to any other rifamycins.

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - rifabutin (unii: 1w306tda6s) (rifabutin - unii:1w306tda6s) - rifabutin 150 mg - rifabutin capsules usp are indicated for the prevention of disseminated mycobacterium avium complex (mac) disease in patients with advanced hiv infection. rifabutin capsules are contraindicated in patients who have had clinically significant hypersensitivity to rifabutin or to any other rifamycins.

United States - English - NLM (National Library of Medicine)

eon labs, inc. - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr) - rifampin 150 mg - in the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. if test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. rifampin is indicated in the treatment of all forms of tuberculosis. a three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of short-course therapy which is usually continued for 2 months. the advisory council for the elimination of tuberculosis, the american thoracic

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr) - rifampin 600 mg - in the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin for injection, usp and they should be repeated throughout therapy to monitor the response to treatment.  since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. if test results show resistance to rifampin for injection, usp and the patient is not responding to therapy, the drug regimen should be modified. rifampin for injection, usp is indicated in the treatment of all forms of tuberculosis. a three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of short-course therapy which is usually continued for 2 months. the advisory council f